Tolerx, Inc. Cuts Staff, Auctioning Assets After Phase 3 Failure
10/7/2011 9:31:26 AM
More...
|
Tolerx, Inc. Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
4/5/2011 7:18:12 AM
More...
|
Tolerx, Inc. and GlaxoSmithKline (GSK) Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
3/11/2011 7:13:01 AM
More...
|
Tolerx, Inc. Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
2/9/2011 7:55:27 AM
More...
|
Tolerx, Inc. Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
12/14/2010 7:21:11 AM
More...
|
Tolerx, Inc. and the Cancer Research Institute Enter Collaboration to Accelerate Development of TRX518, a First-in-Class Anti-GITR Antibody for Cancer Treatment
12/1/2010 7:29:16 AM
More...
|
Tolerx, Inc. Forms Scientific Advisory Board to Advance Research in Type 1 Diabetes
11/2/2010 11:24:02 AM
More...
|
Tolerx, Inc. Presents Research at European Diabetes Meeting and Enrolls First Patient in Europe in the DEFEND-2 Phase 3 Clinical Study in Type 1 Diabetes
9/23/2010 8:33:27 AM
More...
|
Tolerx, Inc. Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
8/4/2010 9:16:59 AM
More...
|
Tolerx, Inc. Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
6/28/2010 9:12:55 AM
More...
|
|